Oxaliplatin injection

DRUG16 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sixth Affiliated Hospital, Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd., BeBetter Med Inc, Fujian Cancer Hospital

Conditions

AdenocarcinomaAdvanced Biliary CancerAdvanced Solid TumorAdvanced Solid TumourAdvanced/Metastatic Colorectal CancerCLDN18.2-positive Advanced Biliary Tract CancerColorectal CarcinomaDiffuse Large B-cell Lymphoma

Phase 1

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BeBetter Med IncRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2023-12-01End: 2025-11-05Target: 75Updated: 2023-12-11

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Not yet recruitingNCT07298772

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Advanced Solid Tumor

Start: 2025-12-31End: 2028-01-31Target: 198Updated: 2025-12-23

Phase 2

mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer

Sixth Affiliated Hospital, Sun Yat-sen UniversityAdvanced/Metastatic Colorectal Cancer

Start: 2022-07-20End: 2023-12-31Target: 18Updated: 2023-02-28

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Qilu Pharmaceutical Co., Ltd.Colorectal Carcinoma

Start: 2022-09-29End: 2025-09-30Target: 60Updated: 2023-05-25

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Not yet recruitingNCT05976568

Qilu Pharmaceutical Co., Ltd.Hepatocellular Carcinoma

Start: 2023-09-01End: 2027-09-01Target: 668Updated: 2023-08-04

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Not yet recruitingNCT06942767

Qilu Pharmaceutical Co., Ltd.Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Start: 2025-06-30End: 2028-03-31Target: 100Updated: 2025-04-27

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Not yet recruitingNCT07151872

Qilu Pharmaceutical Co., Ltd.CLDN18.2-positive Advanced Biliary Tract Cancer

Start: 2025-09-30End: 2026-10-31Target: 120Updated: 2025-09-03

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

Not yet recruitingNCT07383285

Peking University Cancer Hospital & InstituteRectal Neoplasms Malignant

Start: 2026-02-01End: 2029-12-31Target: 106Updated: 2026-02-03

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Not yet recruitingNCT07390383

Nanjing Leads Biolabs Co.,LtdAdvanced Solid Tumour

Start: 2026-04-01End: 2028-05-30Target: 110Updated: 2026-04-01

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Not yet recruitingNCT07392866

Nanjing Sanhome Pharmaceutical, Co., Ltd.Hepatocellular Carcinoma (HCC)

Start: 2026-03-01End: 2030-03-01Target: 120Updated: 2026-02-09

Phase 3

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Biliary Cancer

Start: 2021-02-04End: 2023-02-01Target: 392Updated: 2021-03-22

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

RecruitingNCT06792253

BeBetter Med IncRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2025-01-06End: 2029-06-30Target: 416Updated: 2025-01-24

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

RecruitingNCT06793917

Fujian Cancer HospitalGastric Cancer

Start: 2025-06-07End: 2029-04-01Target: 269Updated: 2025-07-20

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

RecruitingNCT06929624

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Diffuse Large B-cell Lymphoma

Start: 2025-04-24End: 2028-01-31Target: 280Updated: 2025-11-18

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Not yet recruitingNCT07385703

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Adenocarcinoma

Start: 2026-03-01End: 2030-05-01Target: 752Updated: 2026-02-04

A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Not yet recruitingNCT07449780

AkesoGastric / Gastroesophageal Junction Adenocarcinoma

Start: 2026-03-31End: 2028-02-15Target: 422Updated: 2026-03-04

Related Papers

SYLT-030: Efficacy and safety of tislelizumab plus mFOLFOX6 versus tislelizumab plus POF (paclitaxel + mFOLFOX6) as first-line therapy for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): A multicenter, open-label, randomized phase III trial.

Journal of Clinical Oncology2026-01-10

Efficacy and safety of ifupinostat (BEBT-908) in combination with rituximab for relapsed/refractory diffuse large B-cell lymphoma: Results from an exploratory phase Ib study.

Journal of Clinical Oncology2025-05-281 citations